Shiloh
Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2019/10/news-scan-oct-11-2019
News Scan for Oct 11, 2019
Polio in Pakistan, Africa; Billions for HIV, TB, malaria; High-dose vs adjuvanted flu vaccine
Filed Under:
Polio; Tuberculosis; Malaria; Influenza Vaccines
[h=3]More polio in Pakistan, DRC, Central African Republic[/h] In its latest weekly update, the Global Polio Eradication Initiative (GPEI) said today that Pakistan recorded three new cases of wild poliovirus type 1 (WPV1) this week, and the Democratic Republic of the Congo (DRC) and the Central African Republic recorded new cases of vaccine-derived poliovirus type 2 (cVDPV2).
In Pakistan, the three patients with WPV1 experienced symptom onset between Aug 26 and Sep 13. "There are now 72 WPV1 cases reported in 2019. In 2018, there were 12 WPV1 cases," the GPEI said.
In the DRC, officials recorded three cVDPV2 cases, which raise 2019's total in that country to 34, compared with 20 in 2018. In the Central African Republic, four cases of cVDPV2 were reported in the last week, bringing the country's total so far this year to 10 cases.
2019 has had almost triple the number of cases of wild poliovirus than 2018—88 to date, compared with 2018's total of 33. So far this year, officials have confirmed 95 vaccine-derived polio cases; last year, the total reached 104.
Last week the World Health Organization (WHO) said mounting cases of polio have secured the disease's status as a global public health emergency and expressed specific concern for the ongoing transmission in Pakistan.
Oct 11 GPEI update
[h=3]WHO’s global fund gets $14 billion boost from donors[/h] A group of donors at the WHO's Global Fund's sixth replenishment conference in Lyon, France, pledged $14.02 billion to fight HIV, tuberculosis (TB), and malaria, the agency said in a news release today.
The funds will cover a 3-year period, from 2020 through 2022. The WHO said the money will go to more than 110 countries and will help scale up infectious diseases responses, including drug resistance and surveillance systems.
"The replenishment of the Global Fund is not just an investment in one organization or three diseases; it’s an investment in our shared vision of a healthier, safer and fairer world," said WHO Director-General Tedros Adhanom Ghebreyesus, PhD. "This commitment is a strong statement that the fight against infectious diseases can be won, and that our commitment to 'end the epidemics' and 'leave no one behind' are not empty slogans."
The Global Fund was set up by the WHO in 2002 to help countries establish and sustain nationally driven programs to fight HIV, TB and malaria—preventable and treatable diseases that kill more than 2.6 million people worldwide each year.
Oct 10 WHO press release
[h=3]High-dose flu vaccine outperforms adjuvanted version by 1 measure[/h] A large retrospective US cohort study has determined that a trivalent (three-strain) high-dose inactivated influenza vaccine (HD-IIV3) is about 12% more effective in preventing respiratory-related hospitalizations than an adjuvanted trivalent inactivated flu vaccine (aIIV3) among people 65 and older.
Writing in Vaccine, researchers from Sanofi Pasteur and three universities said they analyzed data from Optum's Clinformatics Data Mart to compare outcome rates between seniors who received HD-IIV3 or aIIV3 during the 2016-17 and 2017-18 flu seasons, in which the H3N2 flu strain predominated. All told, 842,282 adults aged 65 and older received the high-dose version and 34,157 the adjuvanted vaccine. An adjuvant is an immune-boosting additive.
Pooled relative vaccine effectiveness for HD-IIV3 versus aIIV3 for respiratory-related hospitalizations over both seasons was 12% (95% confidence interval [CI], 3.3% to 20%). It was 13% (95% CI, −6.4% to 32%) for the 2016-17 season and 12% (95% CI, 2.1% to 21%) for the 2017-18 season.
Oct 9 Vaccine abstract
News Scan for Oct 11, 2019
Polio in Pakistan, Africa; Billions for HIV, TB, malaria; High-dose vs adjuvanted flu vaccine
Filed Under:
Polio; Tuberculosis; Malaria; Influenza Vaccines
[h=3]More polio in Pakistan, DRC, Central African Republic[/h] In its latest weekly update, the Global Polio Eradication Initiative (GPEI) said today that Pakistan recorded three new cases of wild poliovirus type 1 (WPV1) this week, and the Democratic Republic of the Congo (DRC) and the Central African Republic recorded new cases of vaccine-derived poliovirus type 2 (cVDPV2).
In Pakistan, the three patients with WPV1 experienced symptom onset between Aug 26 and Sep 13. "There are now 72 WPV1 cases reported in 2019. In 2018, there were 12 WPV1 cases," the GPEI said.
In the DRC, officials recorded three cVDPV2 cases, which raise 2019's total in that country to 34, compared with 20 in 2018. In the Central African Republic, four cases of cVDPV2 were reported in the last week, bringing the country's total so far this year to 10 cases.
2019 has had almost triple the number of cases of wild poliovirus than 2018—88 to date, compared with 2018's total of 33. So far this year, officials have confirmed 95 vaccine-derived polio cases; last year, the total reached 104.
Last week the World Health Organization (WHO) said mounting cases of polio have secured the disease's status as a global public health emergency and expressed specific concern for the ongoing transmission in Pakistan.
Oct 11 GPEI update
[h=3]WHO’s global fund gets $14 billion boost from donors[/h] A group of donors at the WHO's Global Fund's sixth replenishment conference in Lyon, France, pledged $14.02 billion to fight HIV, tuberculosis (TB), and malaria, the agency said in a news release today.
The funds will cover a 3-year period, from 2020 through 2022. The WHO said the money will go to more than 110 countries and will help scale up infectious diseases responses, including drug resistance and surveillance systems.
"The replenishment of the Global Fund is not just an investment in one organization or three diseases; it’s an investment in our shared vision of a healthier, safer and fairer world," said WHO Director-General Tedros Adhanom Ghebreyesus, PhD. "This commitment is a strong statement that the fight against infectious diseases can be won, and that our commitment to 'end the epidemics' and 'leave no one behind' are not empty slogans."
The Global Fund was set up by the WHO in 2002 to help countries establish and sustain nationally driven programs to fight HIV, TB and malaria—preventable and treatable diseases that kill more than 2.6 million people worldwide each year.
Oct 10 WHO press release
[h=3]High-dose flu vaccine outperforms adjuvanted version by 1 measure[/h] A large retrospective US cohort study has determined that a trivalent (three-strain) high-dose inactivated influenza vaccine (HD-IIV3) is about 12% more effective in preventing respiratory-related hospitalizations than an adjuvanted trivalent inactivated flu vaccine (aIIV3) among people 65 and older.
Writing in Vaccine, researchers from Sanofi Pasteur and three universities said they analyzed data from Optum's Clinformatics Data Mart to compare outcome rates between seniors who received HD-IIV3 or aIIV3 during the 2016-17 and 2017-18 flu seasons, in which the H3N2 flu strain predominated. All told, 842,282 adults aged 65 and older received the high-dose version and 34,157 the adjuvanted vaccine. An adjuvant is an immune-boosting additive.
Pooled relative vaccine effectiveness for HD-IIV3 versus aIIV3 for respiratory-related hospitalizations over both seasons was 12% (95% confidence interval [CI], 3.3% to 20%). It was 13% (95% CI, −6.4% to 32%) for the 2016-17 season and 12% (95% CI, 2.1% to 21%) for the 2017-18 season.
Oct 9 Vaccine abstract